Shattuck Labs Reports Q1 2025: Net Loss Narrowed to $13.7M, EPS Improved to $0.27

Reuters

05/02

Shattuck Labs Reports Q1 2025: Net Loss Narrowed to $13.7M, EPS Improved to $0.27

Shattuck Labs Inc., a biotechnology company, has announced its financial results for the first quarter of 2025. The company reported a net loss of $13.7 million for the quarter ended March 31, 2025, compared to a net loss of $18.5 million for the same quarter in 2024. The cash and cash equivalents, along with investments, stood at $60.9 million as of March 31, 2025, down from $114.6 million as of March 31, 2024. Research and Development expenses were recorded at $9.9 million, a decrease from $16.3 million in the previous year's corresponding quarter. General and Administrative expenses also saw a reduction, amounting to $4.5 million compared to $4.9 million in the first quarter of 2024. A significant business update includes the advancement of Shattuck's SL-325 program, with an Investigational New Drug $(IND.AU)$ filing anticipated in the third quarter of 2025. The company also participated in the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025, with CEO Taylor Schreiber presenting at the event. Shattuck's current cash balance is expected to fund operations into 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9443124-en) on May 01, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2532833714"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2532833714\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2532833714?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-02 04:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2532833714","market":"nz","top_or_hot":-1,"title":"Shattuck Labs Reports Q1 2025: Net Loss Narrowed to $13.7M, EPS Improved to $0.27","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Shattuck Labs Reports Q1 2025: Net Loss Narrowed to $13.7M, EPS Improved to $0.27\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Shattuck Labs Inc., a biotechnology company, has announced its financial results for the first quarter of 2025. The company reported a net loss of $13.7 million for the quarter ended March 31, 2025, compared to a net loss of $18.5 million for the same quarter in 2024. The cash and cash equivalents, along with investments, stood at $60.9 million as of March 31, 2025, down from $114.6 million as of March 31, 2024. Research and Development expenses were recorded at $9.9 million, a decrease from $16.3 million in the previous year's corresponding quarter. General and Administrative expenses also saw a reduction, amounting to $4.5 million compared to $4.9 million in the first quarter of 2024. A significant business update includes the advancement of Shattuck's SL-325 program, with an Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> filing anticipated in the third quarter of 2025. The company also participated in the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025, with CEO Taylor Schreiber presenting at the event. Shattuck's current cash balance is expected to fund operations into 2027.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9443124-en) on May 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shattuck Labs Reports Q1 2025: Net Loss Narrowed to $13.7M, EPS Improved to $0.27</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShattuck Labs Reports Q1 2025: Net Loss Narrowed to $13.7M, EPS Improved to $0.27\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-02 04:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Shattuck Labs Reports Q1 2025: Net Loss Narrowed to $13.7M, EPS Improved to $0.27\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Shattuck Labs Inc., a biotechnology company, has announced its financial results for the first quarter of 2025. The company reported a net loss of $13.7 million for the quarter ended March 31, 2025, compared to a net loss of $18.5 million for the same quarter in 2024. The cash and cash equivalents, along with investments, stood at $60.9 million as of March 31, 2025, down from $114.6 million as of March 31, 2024. Research and Development expenses were recorded at $9.9 million, a decrease from $16.3 million in the previous year's corresponding quarter. General and Administrative expenses also saw a reduction, amounting to $4.5 million compared to $4.9 million in the first quarter of 2024. A significant business update includes the advancement of Shattuck's SL-325 program, with an Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> filing anticipated in the third quarter of 2025. The company also participated in the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025, with CEO Taylor Schreiber presenting at the event. Shattuck's current cash balance is expected to fund operations into 2027.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9443124-en) on May 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"STTK","symbol_name":"Shattuck Labs, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nNDL92DSMW:1","article_id":"2532833714","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2532833714","pubTimestamp":1746131280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Shattuck Labs Inc., a biotechnology company, has announced its financial results for the first quarter of 2025. The company reported a net loss of $13.7 million for the quarter ended March 31, 2025, compared to a net loss of $18.5 million for the same quarter in 2024. The cash and cash equivalents, along with investments, stood at $60.9 million as of March 31, 2025, down from $114.6 million as of March 31, 2024. Research and Development expenses were recorded at $9.9 million, a decrease from $16.3 million in the previous year's corresponding quarter. General and Administrative expenses also saw a reduction, amounting to $4.5 million compared to $4.9 million in the first quarter of 2024. A significant business update includes the advancement of Shattuck's SL-325 program, with an Investigational New Drug  filing anticipated in the third quarter of 2025. The company also participated in the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025, with CEO Taylor Schreiber prese","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"STTK":"Shattuck Labs, Inc.","NDAQ":"纳斯达克OMX交易所"},"translate_title":"Shattuck Labs报告2025年第一季度：净亏损收窄至1,370万美元，每股收益改善至0.27美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"STTK":0.9},"content_text":"Shattuck Labs Reports Q1 2025: Net Loss Narrowed to $13.7M, EPS Improved to $0.27\n    \n\n        Shattuck Labs Inc., a biotechnology company, has announced its financial results for the first quarter of 2025. The company reported a net loss of $13.7 million for the quarter ended March 31, 2025, compared to a net loss of $18.5 million for the same quarter in 2024. The cash and cash equivalents, along with investments, stood at $60.9 million as of March 31, 2025, down from $114.6 million as of March 31, 2024. Research and Development expenses were recorded at $9.9 million, a decrease from $16.3 million in the previous year's corresponding quarter. General and Administrative expenses also saw a reduction, amounting to $4.5 million compared to $4.9 million in the first quarter of 2024. A significant business update includes the advancement of Shattuck's SL-325 program, with an Investigational New Drug $(IND.AU)$ filing anticipated in the third quarter of 2025. The company also participated in the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025, with CEO Taylor Schreiber presenting at the event. Shattuck's current cash balance is expected to fund operations into 2027.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9443124-en) on May 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}